Thymopentin dosage in published studies and labels

These are the doses used for Thymopentin in FDA labelling and published clinical studies, reported as each source states them, one row per regimen. They describe what was studied or approved for a specific population. They are not a recommendation, and none of them is a dose for any individual.

Research and educational reference only. This is not medical advice, and no figure on this page is a dosing recommendation.

Last checked against primary sources: November 7, 2026

Studied regimens and sources

Thymopentin has human dosing evidence from randomised trials of the 1980s and 1990s. The trials that state their dose used 50 mg three times a week: by slow intravenous injection for 3 weeks in rheumatoid arthritis, and by subcutaneous injection for 12 weeks in severe atopic dermatitis and for 24–52 weeks in HIV infection. Thymopentin is not FDA-approved and has no DailyMed listing.

Clinical Trial Evidence

Dosage evidence summary for Thymopentin
Human dosing established	Yes
Studied dose range	50 mg three times a week in the published trials; 10 mg twice a week in one registered trial
Route	Subcutaneous · Intravenous (slow injection, in the rheumatoid arthritis trials)
Frequency	Three times a week in the published trials
Duration studied	3 weeks (rheumatoid arthritis) to 12 weeks (atopic dermatitis) and 24–52 weeks (HIV)
Evidence level	Clinical Trial Evidence
Last reviewed	2026-11-07

Research-reported dosing

Doses as studied, one row per regimen. Different trials used different regimens; they are listed separately rather than averaged.

Research-reported dosing for Thymopentin, one row per studied regimen
Study / context	Population	Dose	Route	Frequency	Duration	Outcome studied	Source
Active rheumatoid arthritis, Lancet trial (1985)Clinical trial · Randomised double-blind placebo-controlled trial	Adults with active rheumatoid arthritis (n=41; 21 thymopentin, 20 placebo)	50 mg, given in fractions over 10 minutes	Slow intravenous injection	Three times a week	3 weeks	Less joint tenderness, swelling and morning pain than placebo; a trend to relapse 4 weeks after stopping	Treatment of active rheumatoid arthritis with slow intravenous injections of thymopentin. A double-blind placebo-controlled randomised study. Lancet. 1985.
Rheumatoid arthritis, multicentre UK trial (1989)Clinical trial · Randomised placebo-controlled multicentre trial	Adults with rheumatoid arthritis (n=76)	50 mg	Slow intravenous injection	Three times a week	3 weeks, with follow-up to 7 weeks	Ritchie index and swollen joint score improved more than with placebo; toxicity minimal	Thymopentin (TP-5) in the treatment of rheumatoid arthritis. Br J Rheumatol. 1989.
Severe atopic dermatitis, adjunct to topical steroids (1994)Clinical trial · Randomised double-blind placebo-controlled trial	Patients aged 2 years and older with severe atopic dermatitis on at least 20% of the skin (n=39)	50 mg	Subcutaneous	Three times a week	12 weeks	Greater improvement than placebo; no thymopentin-related adverse events reported	A double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of thymopentin as an adjunctive treatment in atopic dermatitis. J Am Acad Dermatol. 1994.
Moderate to severe atopic dermatitis, two-centre trial (1990)Clinical trial · Randomised double-blind placebo-controlled trial	Patients with moderate to severe atopic dermatitis (n=100; 48 thymopentin, 52 placebo)	Not stated in the indexed abstract	Subcutaneous	Daily	6 weeks	Larger fall in clinical severity score than placebo (p = 0.04), with less itching and redness	Thymopentin therapy reduces the clinical severity of atopic dermatitis. J Allergy Clin Immunol. 1990.
HIV infection without AIDS (1992)Clinical trial · Randomised double-blind placebo-controlled trial	HIV-positive adults without AIDS (n=91; 52 asymptomatic, 39 symptomatic)	50 mg	Subcutaneous	Three times a week	24 or 52 weeks	Asymptomatic patients kept more CD4+ cells than with placebo; no difference in symptomatic patients	Maintenance of CD4+ cells by thymopentin in asymptomatic HIV-infected subjects: results of a double-blind, placebo-controlled study. AIDS. 1992.
HIV infection treated with zidovudine (1995)Clinical trial · Randomised double-blind placebo-controlled trial	Asymptomatic HIV-positive adults on zidovudine with 200–500 CD4 cells/mm3 (n=352)	50 mg	Subcutaneous	Three times a week	48 weeks of evaluation	Fewer progressions to AIDS or death in people with more than 6 months of prior zidovudine; no difference in those with less	Safety and efficacy of thymopentin in zidovudine (AZT)-treated asymptomatic HIV-infected subjects with 200-500 CD4 cells/mm3: a double-blind placebo-controlled trial. J Acquir Immune Defic Syndr Hum Retrovirol. 1995.
NCT00460681 — phase 3, after resection of small hepatocellular carcinomaClinical trial · Phase 3 registered trial, status unknown	Patients after curative resection of small hepatocellular carcinoma (estimated n=220)	10 mg	Subcutaneous or intramuscular	Every second day (twice a week, as the record states)	3 months	Not reported; status unknown and no results posted	NCT00460681 — Study of Thymopentin in Patients After Curative Resection of Small Hepatocellular Carcinoma

Where sources disagree

The 50 mg three-times-weekly regimen is consistent across the trials that state a dose, but the route is not: rheumatoid arthritis trials gave it by slow intravenous injection, and the dermatitis and HIV trials by subcutaneous injection.
Results were mixed. A 6-month course in chronic hepatitis B was reported as not effective (PubMed 7836705), and the 1995 HIV trial found benefit in only one of its two groups.
The registered liver cancer trial used a different regimen (10 mg every second day for 3 months), and its record calls this both every second day and twice a week. It has posted no results.
Thymopentin is not FDA-approved and has no DailyMed listing. The trial doses come from people with specific diseases under medical supervision; no trial studied healthy people.